Novogen has three distinct technologies (PI3K inhibitors, superbenzopyran and anti-tropomyosin), each with the ability to yield a pipeline of future development candidates.

The PI3K (phosphoinositide 3-kinase) inhibitor functions by inhibiting an important signalling pathway that is thought to be critical to the development of certain kinds of tumours.

The superbenzopyran (SBP) platform targets slower-dividing 'tumour-initiating cells' thereby helping combat the problems of resistance and recurrence that occur with chemotherapy.

The anti-tropomyosin (ATM) platform is a novel therapy with broad applications, which enhances the activity of existing, widely-used chemo agents, potentially reducing resistance and toxicity.